The ADINA Act (Allergen Disclosure In Non-food Articles Act) would amend the Federal Food, Drug, and Cosmetic Act to require that the label of any drug intended for human use identify each ingredient that is, or is derived from, a major food allergen or a gluten-containing grain. For such ingredients, the label must state that the drug contains the ingredient and identify the specific source grain (e.g., wheat, barley, rye, or their crossbred hybrids). If a drug’s label fails to disclose these ingredients or the grain source, it would be considered misbranding. The new labeling requirement would take effect on the earlier of a date determined by the Secretary of Health and Human Services or two years after enactment. In short, the bill aims to improve transparency about allergen and gluten-derived ingredients in human-use drugs, helping allergy and celiac patients avoid exposures through medications.